Value
6.3/10data confidence 100%| Component | Sub-score |
|---|---|
| P/E | 6.3 |
| P/S | 9.3 |
| EV/EBITDA | 3.6 |
| Fwd P/E | 8.0 |
| PEG | 7.9 |
| Analyst target | 3.0 |
- ▸Forward P/E: 15.1x
- ▸PEG: 0.86
PHG · Why this verdict
Why Koninklijke Philips N.V. NY Reg (PHG) is rated HOLD
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictHOLD
Overall score5.9/10
ConfidenceMEDIUM
MacroRISK_OFF
TrendMatrix Research · core thesis
Engine thesis — one sentence
Philips has delivered four consecutive earnings beats with an average surprise of 39.4% and free cash flow at 157% of net income, but trades below its 200-day moving average with declining revenues of -5% and a below-average quality score of 4.7.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Philips has beaten earnings estimates in all 4 of the last 4 quarters with an exceptional average surprise of 39.4%, the largest magnitude beat streak in the data, suggesting analyst estimates are consistently too conservative. Catalyst breakdown | Earnings beat streak extends to 6 quarters with average surprise remaining above 25%, continuing to outperform consensus. | →Stable |
| CounterConsistently large positive surprises may indicate management is guiding low rather than that the business is structurally improving; eventually consensus adjusts and beats shrink. | ||
Revenue is declining at -5% annually, the quality score sits at 4.7, and the stock trades below its 200-day moving average — key concerns that offset the strong earnings beat pattern. Growth breakdown | Revenue returns to flat or positive growth and quality score rises above 5.5 within 12 months. | →Stable |
| CounterRevenue decline in medical devices often precedes a rebound as product cycles reset; the 157% free cash flow conversion relative to net income suggests the business generates real cash even during revenue headwinds. | ||
Free cash flow is 157% of net income with a Piotroski F-Score of 7 out of 9, indicating that Philips converts reported earnings into cash at a rate well above par, supporting balance sheet stability. Quality breakdown | Free cash flow conversion remains above 120% of net income for 4 consecutive quarters. | →Stable |
| CounterWithout a recognized competitive moat and with declining revenues, even strong cash conversion may not prevent further margin compression as the turnaround remains uncertain. | ||
At a forward P/E of 13.1x and PEG ratio of 0.87, Philips is reasonably valued with a 9.3% upside to the analyst target of $29.18 from a current price of $26.69. Targets | Price rises above $29.00 within 12 months as earnings beats support a valuation re-rating. | ↓Deteriorating |
| CounterA 9.3% upside is a thin margin of safety, and if revenues continue declining the analyst target may be revised downward, eliminating the current cushion. | ||
Philips has beaten earnings estimates in all 4 of the last 4 quarters with an exceptional average surprise of 39.4%, the largest magnitude beat streak in the data, suggesting analyst estimates are consistently too conservative.
→StableCatalyst breakdown
- Expectation
- Earnings beat streak extends to 6 quarters with average surprise remaining above 25%, continuing to outperform consensus.
CounterConsistently large positive surprises may indicate management is guiding low rather than that the business is structurally improving; eventually consensus adjusts and beats shrink.
Revenue is declining at -5% annually, the quality score sits at 4.7, and the stock trades below its 200-day moving average — key concerns that offset the strong earnings beat pattern.
→StableGrowth breakdown
- Expectation
- Revenue returns to flat or positive growth and quality score rises above 5.5 within 12 months.
CounterRevenue decline in medical devices often precedes a rebound as product cycles reset; the 157% free cash flow conversion relative to net income suggests the business generates real cash even during revenue headwinds.
Free cash flow is 157% of net income with a Piotroski F-Score of 7 out of 9, indicating that Philips converts reported earnings into cash at a rate well above par, supporting balance sheet stability.
→StableQuality breakdown
- Expectation
- Free cash flow conversion remains above 120% of net income for 4 consecutive quarters.
CounterWithout a recognized competitive moat and with declining revenues, even strong cash conversion may not prevent further margin compression as the turnaround remains uncertain.
At a forward P/E of 13.1x and PEG ratio of 0.87, Philips is reasonably valued with a 9.3% upside to the analyst target of $29.18 from a current price of $26.69.
↓DeterioratingTargets
- Expectation
- Price rises above $29.00 within 12 months as earnings beats support a valuation re-rating.
CounterA 9.3% upside is a thin margin of safety, and if revenues continue declining the analyst target may be revised downward, eliminating the current cushion.
Per-dimension breakdown
Quality
5.4/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 3.4 |
| ROA | 2.7 |
| Gross margin | 5.2 |
| Op margin | 5.6 |
| Net margin | 3.2 |
| Current ratio | 4.8 |
| FCF quality | 9.6 |
| Moat | 5.2 |
| Piotroski F | 8.9 |
- ▸Excellent cash conversion: 137% FCF/NI
- ▸No competitive moat
- ▸Strong Piotroski F-Score: 8/9
Growth
6.3/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 2.6 |
| EPS growth | 10.0 |
Momentum
7.6/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.6 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 7.5 |
| Volume | 6.9 |
- ▸Overbought (RSI 87)
- ▸Volume accumulation (rising OBV)
- ▸Above 200-MA but MA slope flat/negative + RSI 87 (late-cycle distribution risk)
Sentiment
5.6/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 6.5 |
| Analyst rating | 5.0 |
| Price target | 5.5 |
Insider
5.0/10data confidence 50%Peer rank
4.6/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 7.4 |
| quality rank | 5.9 |
| growth rank | 1.0 |
Technical
3.3/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.0 |
| support resistance | 0.1 |
| 52w position | 9.1 |
| gap | 4.0 |
Risk (lower is worse)
7.0/10data confidence 100%| Component | Sub-score |
|---|---|
| days to cover | 8.3 |
| volatility | 6.7 |
| put call | 8.9 |
| implied vol | 6.7 |
| max pain risk | 3.0 |
| beta | 8.1 |
| debt equity | 7.1 |
- ▸Above max pain $17
Catalyst
7.2/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| surprise avg | 10.0 |
| dividend safety | 6.0 |
| news activity | 5.0 |
- ▸Perfect beat streak: 4Q
- ▸Dividend: 3.7%
How the verdict was assembled
Engine trigger
Maintain position. Not compelling to add more.
Engine technical detail
verdict_path:
L4:PATH_F_HOLD|L3:NEWS_MOD_NO_UPSIDEPassed (6)
- MOMENTUM:7.6>=5.5
- INSIDER:OK
- 8K:CLEAN
- EARNINGS_PROXIMITY:NO_DATE
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:-0.7=NEGATIVE
Warning (1)
- DEATH_CROSS:momentum=7.6>=5.0 recovering
Reward-to-Risk
-0.68
Upside
-10.1%
Downside
15.0%
Sizing output
AVOID
SetupRecovery — Death cross but MACD improving, RSI 87
EdgeNo clear edge — No clear edge identified
SuitabilityModerate — Balanced profile
Investment implication
None of the engine's positive-conviction paths (C-quality, D-momentum) triggered — the F-path HOLD reflects balanced signals. Strongest-cleared gate: MOMENTUM:7.6>=5.5. Top dim: Momentum at 7.6; weakest: Technical at 3.3. No conviction either direction.
The strongest dimensions are Momentum at 7.6, Catalyst at 7.2, and Risk (lower is worse) at 7.0; the weakest are Technical at 3.3, Peer rank at 4.6, and Insider at 5.0. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of -0.68 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Earnings Beat Streak Strength
Trip ifEarnings miss consensus by more than 10% in any 1 of the next 2 quarterly reports, breaking the 39% average beat pattern.
- P2Revenue Decline Quality Gap
Trip ifRevenue declines more than 8% year-over-year for 2 consecutive quarters, indicating accelerating contraction beyond the current -5% rate.
- P3Free Cashflow Conversion
Trip ifFree cash flow conversion falls below 80% of net income for 2 consecutive quarters, signaling cash generation deterioration.
- P4Valuation Analyst Upside
Trip ifAnalyst consensus price target falls below $24.00, eliminating the current 9.3% upside cushion and pushing implied return below 0%.